Literature DB >> 8472724

Renovascular hypertension and coronary heart disease complicating essential thrombocythemia.

D O Arnar1, M K Pétursson, E Jónmundsson, J Björnsdóttir.   

Abstract

A 36-year-old male was evaluated for treatment-resistant hypertension. A high platelet count 828 x 10(9).l-1, led to the diagnosis of essential thrombocythemia (ET). Aorto-renal angiography revealed critical bilateral renal artery stenosis and coronary angiography showed three-vessel disease. Percutaneous transluminal renal angioplasty was only partially successful. The patient received a 12-week course of busulphan and subsequently the thrombocyte count decreased to 200 x 10(9).l-1. Renal angiography 12 months later showed bilateral regression of the renal artery stenosis with lowering of the blood pressure to normal levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8472724     DOI: 10.1093/eurheartj/14.4.576

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

Review 1.  Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review.

Authors:  Beste Ozben; Ahmet Ekmekci; Zehra Bugra; Sabahattin Umman; Mehmet Meric
Journal:  J Thromb Thrombolysis       Date:  2006-08       Impact factor: 2.300

2.  Erythromelalgia as a presenting manifestation in a patient with essential thrombocythemia complicating renovascular hypertension due to unilateral renal artery stenosis.

Authors:  Jin-Wuk Hur; Young-Yiul Lee; Woong-Soo Lee; Jae-Bum Jun
Journal:  Rheumatol Int       Date:  2005-03-05       Impact factor: 2.631

Review 3.  Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.

Authors:  Eikan Mishima; Takehiro Suzuki; Yoichi Takeuchi; Kazumasa Seiji; Noriko Fukuhara; Kei Takase; Hideo Harigae; Takaaki Abe; Sadayoshi Ito
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-14       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.